RENO, NV, October 22nd, 2026, FinanceWire
Sarcomatrix Therapeutics Corp., a Delaware corporation based in Reno, Nevada, today reminded prospective investors that its accredited investor round, conducted under Regulation D, Rule 506(c), is scheduled to close on October 31, 2026, the closing date the company announced on October 1, 2026. The round runs on the KoreInside platform, with KoreTransfer USA LLC acting as transfer agent. The closing date remains subject to earlier closing if the round is fully subscribed or to extension at the company’s discretion, and the company will announce any change to it.
Sarcomatrix is a preclinical-stage company, which means its treatments have not yet been tested in people.
Program Development Update
Since the round opened on July 24, 2026, the company has selected the sulfate salt form of S-969 for development, engaged specialist vendors for drug substance and drug product manufacturing, and expanded its Board of Directors with two independent directors, as announced on September 11, 2026.
The next major step toward human testing is contracting the provider for the two-species Good Laboratory Practice (GLP) toxicology studies that regulators require before a drug can be given to people. The company expects the work required to reach an application to begin human testing to take approximately 12 months from the date that contract is signed. These are plans, not guarantees, and drug development frequently takes longer than expected or fails outright.
Use of Offering Proceeds
As described in the offering materials, proceeds are intended for Investigational New Drug (IND)-enabling nonclinical work, including two-species GLP toxicology; chemistry, manufacturing, and controls (CMC) work on drug substance, drug product, and toxicology formulation; regulatory preparation for a pre-IND meeting and IND assembly; intellectual property prosecution and license compliance; and governance, audit readiness, and working capital. Allocation is at the discretion of the Board of Directors and may change. Proceeds of the round will not fund the company through regulatory approval of any product candidate.
About the Program
S-969 is an oral small molecule that targets a key kinase to upregulate alpha-7 beta-1 integrin (α7β1 integrin), strengthening the connection between muscle fibers and their surrounding support structure and supporting muscle repair. Because this approach does not depend on which genetic mutation a patient carries, it is designed to be relevant across the patient population rather than a single subgroup. S-969 is in preclinical development for Duchenne muscular dystrophy, Becker muscular dystrophy, and limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). An Orphan Drug Designation application for S-969 is in preparation. LAM-111, the company’s second program, holds Orphan Drug Designation in both the United States and the European Union.
From the Company
“Investors who are completing their review should know where the round stands and when it is scheduled to close,” said David Craig, Co-Founder, President, and Chief Executive Officer. “Our focus is unchanged: contract the safety studies and move S-969 toward an application to begin testing in people. We will tell investors plainly if anything about the timing changes.”
How to Participate
This offering is open only to accredited investors, a category defined by the U.S. Securities and Exchange Commission based on income, net worth, or professional credentials. Under Rule 506(c), a company must take reasonable steps to confirm that status, and a self-declaration alone is insufficient. Verification is handled through the offering platform. Accredited investors can review the offering at www.sarcomatrix.com/investors or invest directly at www.sarcomatrix.com/invest. Full offering terms, subscription documents, and complete risk disclosures are provided on the platform once accredited status has been verified. Verification and subscription steps take time to complete, and investors considering participation should allow for that before the scheduled closing date.
About Sarcomatrix Therapeutics Corp.
Sarcomatrix Therapeutics Corp., a Delaware corporation headquartered in Reno, Nevada, is a preclinical-stage biotechnology company developing therapies for muscle-wasting diseases, beginning with Duchenne muscular dystrophy. Its lead candidate, S-969, is an oral small molecule that targets a key kinase to upregulate α7β1 integrin, the primary laminin-binding protein in skeletal and cardiac muscle. A spinout of the University of Nevada, Reno, the company holds the S-969 program under a co-exclusive, worldwide license through the Nevada Research and Innovation Corporation. Its second program, LAM-111, is in development for LAMA2-related congenital muscular dystrophy. Learn more at sarcomatrix.com.
Risk Statement
The Company is a preclinical-stage biopharmaceutical company. It has no approved products, has generated no revenue from product sales, and has not initiated clinical trials. Neither S-969 nor LAM-111 has been tested in humans, and the timeline to an application to begin human testing depends on contracting, manufacturing, regulatory review, and funding, any of which may take longer than planned. The Company will require substantial additional capital to advance its programs, and there is no assurance that such capital will be available on acceptable terms or at all. There is no public market for the Company’s securities, and none is expected to develop. Product candidates in preclinical development frequently fail to advance to or through clinical development. Additional risks are described in the offering materials, which prospective investors should read in full.
Offering Legend
Sarcomatrix Therapeutics Corp. is conducting an offering of securities pursuant to Rule 506(c) of Regulation D under the Securities Act of 1933, as amended. The offering is available exclusively to verified accredited investors as defined in Rule 501(a) of Regulation D. Prospective investors must complete accredited investor verification prior to participation. Securities offered are restricted securities and are subject to limitations on transfer and resale. Investment in early-stage private companies involves a high degree of risk, including the possible loss of the entire investment.
Forward-Looking Statements
This release contains forward-looking statements, including statements regarding the offering and its closing date, development plans, anticipated timelines, regulatory strategy, and potential therapeutic applications. Forward-looking statements are based on current expectations and are subject to significant risks and uncertainties. Actual results may differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law. The Company is not a reporting company under the Securities Exchange Act of 1934, and the statutory safe harbors for forward-looking statements are not available to it.
No Offer
This release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. Any offer is made solely by means of the offering materials made available to verified accredited investors through the Company’s investment platform.